AAX Biotech to present a poster at T-Cell Engager Therapeutics Summit Europe in London

AAX Biotech is pleased to announce its participation in the T-Cell Engager Therapeutics Summit Europe, taking place in London from December 9–11, 2025. This unique event unites leaders in preclinical research, translational science, immunology, and oncology drug development to address key challenges in advancing T-cell engagers (TCEs) to the clinic. 

Ionut Dumitru, PhD, Sr. Scientist, from the AAX Biotech team will be presenting a poster on the critical role of our proprietary Opti-mAb® technology in next-generation therapeutic design. 

Opti-mAb® provides a unique and effective solution to a long-standing challenge in the field: the inherent instability of single-chain variable fragments (scFv). scFv antibodies are crucial components in novel therapeutic formats, including bispecific antibodies and CAR-T cells, but their instability often limits their application. 

Our solution involves a generally applicable molecular stabilization strategy that delivers multiple benefits, including significantly improved production yields and enhanced stability. By stabilizing scFv, Opti-mAb® helps ensure that promising projects reach clinical realization, accelerating the development of more effective T-cell engagers for cancer and autoimmune diseases. 

We look forward to engaging with industry peers, innovators, and potential partners in London to discuss how Opti-mAb® can secure and enhance T-cell engager pipelines.